---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-013659"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:58:36.637664+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insmed's brensocatib fails Phase 2b HS study; program discontinued

## Summary
- Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.
- Secondary efficacy endpoints also not met; Insmed halts HS development of brensocatib.
- Safety consistent with prior studies; no new signals; 40mg dose well tolerated.
- Study enrolled 214 patients at 72 sites; 16-week placebo-controlled phase completed.
- Topline results will be presented at a future medical congress.

## SEC filing metadata
- accession: 0001140361-26-013659
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/0001140361-26-013659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036126013659/ef20070042_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-013659
- JSON: https://secwatch.observer/filing/0001140361-26-013659.json
- Plain text: https://secwatch.observer/filing/0001140361-26-013659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.